TWI680139B - 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途 - Google Patents

短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途 Download PDF

Info

Publication number
TWI680139B
TWI680139B TW107125276A TW107125276A TWI680139B TW I680139 B TWI680139 B TW I680139B TW 107125276 A TW107125276 A TW 107125276A TW 107125276 A TW107125276 A TW 107125276A TW I680139 B TWI680139 B TW I680139B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
treating
item
patent application
scope
Prior art date
Application number
TW107125276A
Other languages
English (en)
Other versions
TW202007695A (zh
Inventor
林万登
Original Assignee
東海大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東海大學 filed Critical 東海大學
Priority to TW107125276A priority Critical patent/TWI680139B/zh
Priority to CN201811100774.6A priority patent/CN110746487B/zh
Application granted granted Critical
Publication of TWI680139B publication Critical patent/TWI680139B/zh
Publication of TW202007695A publication Critical patent/TW202007695A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (5)

  1. 一種一胜肽用於製備促進胰島再生之醫藥組合物之用途，其中，該胜肽之胺基酸序列係由包含有SEQ ID No.2所示序列所組成。
  2. 依據申請專利範圍第1項所述用途，其中，該醫藥組合物係用於治療糖尿病。
  3. 依據申請專利範圍第1項所述用途，其中，該醫藥組合物係用於治療或/及預防高糖誘發心臟病變。
  4. 依據申請專利範圍第3項所述用途，其中，該醫藥組合物係更包含有另一胜肽，其胺基酸序列係為SEQ ID No.1。
  5. 依據申請專利範圍第1項所述用途，其中，該醫藥組合物係用於預防或治療一由糖尿病所引發之疾病，而該由糖尿病引發疾病係選自由糖尿病血管病變、糖尿病肝臟病變、糖尿病腎病及胰島壞死所組成之群。
TW107125276A 2018-07-21 2018-07-21 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途 TWI680139B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TW107125276A TWI680139B (zh) 2018-07-21 2018-07-21 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途
CN201811100774.6A CN110746487B (zh) 2018-07-21 2018-09-20 短胜肽、及其组合物用于治疗/预防糖尿病及与之相关疾病的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW107125276A TWI680139B (zh) 2018-07-21 2018-07-21 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途

Publications (2)

Publication Number Publication Date
TWI680139B true TWI680139B (zh) 2019-12-21
TW202007695A TW202007695A (zh) 2020-02-16

Family

ID=69275648

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107125276A TWI680139B (zh) 2018-07-21 2018-07-21 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途

Country Status (2)

Country Link
CN (1) CN110746487B (zh)
TW (1) TWI680139B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160228503A1 (en) * 2013-09-25 2016-08-11 Pronutria, Inc. Compositions and Formulations for Prevention and Treatment of Diabetes and Obesity, and Methods of Production and Use Thereof in Glucose and Caloric Control

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254167A2 (en) * 2000-01-06 2002-11-06 Monsanto Technology LLC Preparation of deallergenized patatin proteins and patatin permutein proteins
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
CN105566459A (zh) * 2014-10-08 2016-05-11 吴辅佑 可抑制RAGE与Aβ的结合或能与Aβ/RAGE结合的富脯胺酸胜肽及其制备方法
TWI624477B (zh) * 2016-07-05 2018-05-21 Peptide composition and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160228503A1 (en) * 2013-09-25 2016-08-11 Pronutria, Inc. Compositions and Formulations for Prevention and Treatment of Diabetes and Obesity, and Methods of Production and Use Thereof in Glucose and Caloric Control

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Huang et al. "Potato protein hydrolysate attenuates high fat diet-induced cardiac apoptosis through SIRT1/ PGC-1á/Akt signaling" journal of functional foods 12 ( 2 0 1 5 ) 389–398 *

Also Published As

Publication number Publication date
CN110746487B (zh) 2023-12-12
CN110746487A (zh) 2020-02-04
TW202007695A (zh) 2020-02-16

Similar Documents

Publication Publication Date Title
JP2020143164A5 (zh)
JP2017532343A5 (zh)
JP2020507623A5 (zh)
JP2008536483A5 (zh)
JP2019533722A5 (zh)
JP2018511327A5 (zh)
JP2014526441A5 (zh)
JP2008508859A5 (zh)
JP2009017881A5 (zh)
TWI455721B (zh) 癌疫苗組合物
JP2009537143A5 (zh)
JP2006506942A5 (zh)
JP2005537234A5 (zh)
JP2015517489A5 (zh)
JPWO2019156137A5 (zh)
PE20220938A1 (es) Compuestos agonistas de gipr
JP2017532965A5 (zh)
JP2013503110A5 (zh)
JP2006158399A5 (ja) 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤
JP2018538356A5 (zh)
JP2018504112A5 (zh)
JP2008543961A5 (zh)
JP2017521074A5 (zh)
JP2016536357A5 (zh)
JP2017039729A5 (zh)